Report LibraryAll Reports
Datamonitor Healthcare Oncology: NHL: Diffuse Large B-Cell Lymphoma (DLBCL) Disease Coverage
Retail Price: $22,000.00*BioMedTracker Subscriber Price: $15,000.00 - click here to log in
October 09, 2018Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases. The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.
|Indications Covered:||Diffuse Large B-Cell Lymphoma (DLBCL) - NHL|